Aluminum-free borosilicate glass

1. An aluminum-free borosilicate glass, comprising the following glass composition (in weight-% on oxide basis):

SiO 2

70-80;

B 2 O 3

 8-14;

Al 2 O 3

0;

Na 2 O

0-4;

K 2 O

 3-10;

Li 2 O

0;

sum Na 2 O + K 2 O

 3-14;

CaO

0-1;

MgO

0-1;

BaO

0-1;

SrO

0-1;

sum CaO + MgO + BaO + SrO

0-2;

ZnO

0-1;

ZrO 2

3.6-14; 

TiO 2

 0-10;

and

at least one refining agents

0.01-2.0; 

wherein a weight ratio of ZrO 2 : K 2 O is in a range of 1.2:1 to 1.4:1; and

wherein said borosilicate glass has a maximum crystallization rate (KG max ) of ≤0.05 μm/min, measured in a crystallization range of 700 1115° C. and a temperature T (KG max ) of ≤1000° C.

2. The borosilicate glass according to claim 1 , comprising the following glass composition (in weight-% on oxide basis):

SiO 2

70-78;

B 2 O 3

 9-13;

Al 2 O 3

0;

Na 2 O

0.3-3;  

K 2 O

4-8;

Li 2 O

0;

sum Na 2 O + K 2 O

4.3-11; 

CaO

  0-0.5;

MgO

  0-0.5;

BaO

  0-0.5;

SrO

  0-0.5;

sum CaO + MgO + BaO + SrO

0-1;

ZnO

  0-0.75;

ZrO 2

 4.8-11.2;

TiO 2

0-1;

and

at least one refining agents

0.01-2.0; 

wherein the weight ratio of ZrO 2 :K2O is in the range of 1.2:1 to 1.4:1.

3. The borosilicate glass according to claim 1 , wherein the weight ratio of ZrO 2 :K 2 O is in the range of 1.22:1 to 1.4:1.

4. The borosilicate glass according to claim 1 , wherein the sum of Na 2 O+K 2 O is in a range of 3.8 to 12.5 weight-%.

5. The borosilicate glass according to claim 1 , wherein a weight ratio of K 2 O:Na 2 O is >1.0:1.

6. The borosilicate glass according to claim 1 , wherein the glass composition is alkaline earth metal free.

7. The borosilicate glass according to claim 1 , wherein the glass composition does not contain aluminum oxide, alkaline earth metal oxide, lithium oxide, zinc oxide and titanium oxide.

8. The borosilicate glass according to claim 1 , wherein said borosilicate glass has a hydrolytic resistance according to hydrolytic Class 1 according to ISO 720 or USP, a resistance to acids according to acid resistance class S1 according to DIN 12 116, and a resistance to alkali according to alkali resistance class A1 according to ISO 695.

9. A primary pharmaceutical packaging, comprising: a borosilicate glass, comprising the following glass composition (in weight-% on oxide basis):

SiO 2

70-80;

B 2 O 3

 8-14;

Al 2 O 3

0;

Na 2 O

0-4;

K 2 O

 3-10;

Li 2 O

0;

sum Na 2 O + K 2 O

 3-14;

CaO

0-1;

MgO

0-1;

BaO

0-1;

SrO

0-1;

sum CaO + MgO + BaO + SrO

0-2;

ZnO

0-1;

ZrO 2

3.6-14; 

TiO 2

 0-10;

and

at least one refining agents

0.01-2.0; 

wherein a weight ratio of ZrO 2 :K 2 O is in a range of 1.2:1 to 1.4:1; and

wherein said borosilicate glass has a maximum crystallization rate (KG max ) of ≤0.05 μm/min, measured in a crystallization range of 700 1115° C. and a temperature T (KG max ) of ≤1000° C.

10. The primary pharmaceutical packaging according to claim 9 , wherein said primary pharmaceutical packaging is a container for pharmaceutical products.

11. The primary pharmaceutical packaging according to claim 10 , wherein said container is at least one of a bottle, a vial, an injection vial, an ampoule, a cartridge, and a syringe.

12. The primary pharmaceutical packaging according to claim 9 , wherein said primary pharmaceutical packaging is configured to accommodate and store a liquid content substance that has a pH-value in a range of 1 to 11.

13. The primary pharmaceutical packaging according to claim 12 , wherein the liquid content substance is one of an active substance solution, a buffer solution, and a water for injection purposes.

14. A semi-finished product, comprising: a tubular glass, said tubular glass comprising a borosilicate glass comprising the following glass composition (in weight-% on oxide basis):

SiO 2

70-80;

B 2 O 3

 8-14;

Al 2 O 3

0;

Na 2 O

0-4;

K 2 O

 3-10;

Li 2 O

0;

sum Na 2 O + K 2 O

 3-14;

CaO

0-1;

MgO

0-1;

BaO

0-1;

SrO

0-1;

sum CaO + MgO + BaO + SrO

0-2;

ZnO

0-1;

ZrO 2

3.6-14; 

TiO 2

 0-10;

and

at least one refining agents

0.01-2.0; 

wherein a weight ratio of ZrO 2 :K 2 O is in a range of 1.2:1 to 1.4:1; and

wherein said borosilicate glass has a maximum crystallization rate (KG max ) of ≤0.05 μm/min, measured in a crystallization range of 700-1115° C. and a temperature T (KG max ) of ≤1000° C.

15. A pharmaceutical combination, comprising: a primary pharmaceutical packaging consisting of a borosilicate glass comprising the following glass composition (in weight-% on oxide basis):

SiO 2

70-80;

B 2 O 3

 8-14;

Al 2 O 3

0;

Na 2 O

0-4;

K 2 O

 3-10;

Li 2 O

0;

sum Na 2 O + K 2 O

 3-14;

CaO

0-1;

MgO

0-1;

BaO

0-1;

SrO

0-1;

sum CaO + MgO + BaO + SrO

0-2;

ZnO

0-1;

ZrO 2

3.6-14; 

TiO 2

 0-10;

and

at least one refining agents

0.01-2.0; 

wherein a weight ratio of ZrO 2 :K 2 O is in a range of 1.2:1 to 1.4:1; and

wherein said borosilicate glass has a maximum crystallization rate (KG max ) of ≤0.05 μm/min, measured in a crystallization range of 700-1115° C. and a temperature T (KG max ) of ≤1000° C.

16. The pharmaceutical combination according to claim 15 , wherein said primary pharmaceutical packaging is at least one of a bottle, a vial, an injection vial, an ampoule, a cartridge, and a syringe.

17. The pharmaceutical combination according to claim 15 , further comprising a liquid content substance which has a pH value in the range of 1 to 11 within said primary pharmaceutical packaging, wherein said liquid content substance is one of an active substance solution, a buffer solution and a water for injection purposes.